Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD3514

Known as: Androgen Receptor Downregulator AZD3514, SARD AZD3514 
An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
ObjectivesTo investigate the relationships between interferon alpha (IFNα) and the clinical and serological phenotype of patients… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
2018
2018
The androgen receptor (AR) is expressed in 60%–70% of breast cancers regardless of estrogen receptor status, and has been… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
BackgroundThe continual reassessment method (CRM) requires an underlying model of the dose-toxicity relationship (“prior skeleton… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2016
2016
Nausea and vomiting are components of a complex mechanism that signals food avoidance and protection of the body against the… Expand
2015
2015
SummaryBackground AZD3514 is a first-in-class, orally bio-available, androgen-dependent and -independent androgen receptor… Expand
  • table 1
  • table 2
  • figure 1
  • table 5
  • figure 2
Highly Cited
2013
Highly Cited
2013
Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial reduction of the… Expand
2013
2013
BackgroundAZD3514 inhibits and down regulates the androgen receptor (AR) and has undergone clinical trials in prostate cancer. To… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2013
2013
4511 Background: AZD3514 is a first in class, orally bio-available drug that inhibits androgen-dependent and –independent… Expand
2012
2012
The androgen receptor (AR), an important molecular target in the aetiology and progression of prostate cancer, has been found… Expand